Form 4: FibroGen Director James A. Schoeneck Increases Stake in Company

Director James A. Schoeneck reports purchasing FibroGen shares in multiple transactions, increasing his indirect holdings.

Summary

• On March 20, 2025, James A. Schoeneck, a director of FibroGen, Inc., purchased 250,000 shares of common stock at a weighted-average price of $0.352, with individual prices ranging from $0.3499 to $0.3593.
• The purchase was made indirectly through a trust.
• On March 21, 2025, Schoeneck purchased an additional 50,000 shares at a weighted-average price of $0.3408, with individual prices ranging from $0.3341 to $0.3466.
• Following these transactions, Schoeneck indirectly owns 373,722 shares through the trust.
• Schoeneck also disposed of 28,766 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. A director is increasing their stake, which is generally positive, but the amounts are not significant enough to indicate strong conviction. The disposal of shares is a negative.

Positives

• A director increasing their stake in the company could be seen as a positive signal.

Negatives

• The director disposed of 28,766 shares.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholder confidence.

Key Dates

Keywords

FibroGen, FGEN, Schoeneck, Director, Share Purchase, Beneficial Ownership, Form 4